Evaxion A/S: Financial statements 2024
CVR: 31762863
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Evaxion A/S (CVR 31762863) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 22,324,000 and a net result of DKK -73,277,000 compared with DKK -152,414,000 the year before. That is an increase of 4,303.2% compared with the year before. The profit margin was -328.2%. Equity in the 2024 report amounted to DKK -11,780,000. The company had 46 employees in the financial year.
- Revenue
- DKK 22,324,000
- Gross Profit
- DKK 22,324,000
- Profit/Loss
- DKK -73,277,000
- Equity
- DKK -11,780,000
- Total Assets
- DKK 94,669,000
- Employees
- 46
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 22.3 mio. | 22.3 mio. | -73.3 mio. | -11.8 mio. | 46 |
| 2023 | 507 t. | 507 t. | -152.4 mio. | -31.9 mio. | 55 |
| 2022 | - | - | -164.3 mio. | 57.9 mio. | 59 |
| 2021 | - | - | -154.9 mio. | 212.8 mio. | 53 |
| 2020 | - | - | -97.9 mio. | 42.6 mio. | 33 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of November 1, 2024, Thomas Frederik Schmidt is registered as director of Evaxion A/S.
As of October 31, 2024, Jesper Nyegaard Nissen has stepped down as director of Evaxion A/S.
As of June 30, 2024, Niels Iversen Møller has left the board of directors of Evaxion A/S.
Evaxion A/S has published its annual report for 2023. Revenue came to DKK 507,000, and the net result was DKK -152,414,000.
As of April 16, 2024, Lars Aage Staal Wegner has joined the board of directors of Evaxion A/S.
About Evaxion A/S
Evaxion A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2008. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named EVAXION BIOTECH A/S and EVAXION BIOTECH ApS. The management consists of Helen Katrina Tayton-Martin, Andreas Holm Mattsson and Thomas Frederik Schmidt. The board consists of Marianne Søgaard (chair), Jens Bitsch-Nørhave, Lars Holtug and Lars Aage Staal Wegner. The company is owned by BNY (Nominees) Limited (as nominee of The Bank of New York Mellon). The company has 44 employees (2026). In 2025, the company reported revenue of DKK 48,112,000 and a net result of DKK -51,489,000 compared with DKK -73,277,000 the year before. Equity in the 2025 report amounted to DKK 108,250,000.